Table 1:
Proportion of incident cancer cases diagnosed as a first or only primary or second order or higher primary (same or different cancer site) by incident cancer type and age (+/− 65 years), SEER 9, 2009–2013
| Age <65 Years | Age ≥65 Years | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total | First or only primary | Second order or higher primary, same site | Second order or higher primary, different site | Total | First or only primary | Second order or higher primary, same site | Second order or higher primary, different site | |||||||
| N | % | n | % | n | % | n | % | n | % | n | % | |||
| All cancer types | 364961 | 324992 | 89.0% | 12034 | 3.3% | 18353 | 5.0% | 400882 | 299830 | 74.8% | 20736 | 5.2% | 60712 | 15.1% |
| Anus, anal canal, anorectum | 3844 | 3145 | 81.8% | 215 | 5.6% | 321 | 8.4% | 1306 | 905 | 69.3% | 53 | 4.1% | 262 | 20.1% |
| Bone and joints (including soft tissue) | 3306 | 2867 | 86.7% | 84 | 2.5% | 234 | 7.1% | 2329 | 1537 | 66.0% | 79 | 3.4% | 547 | 23.5% |
| Brain and other nervous system | 5141 | 4694 | 91.3% | 79 | 1.5% | 237 | 4.6% | 3559 | 2787 | 78.3% | 8 | 0.2% | 587 | 16.5% |
| Breast (female)1 | 78163 | 68273 | 87.3% | 5318 | 6.8% | 2921 | 3.7% | 52940 | 39753 | 75.1% | 7181 | 13.6% | 3932 | 7.4% |
| Cervix and other female genital organs | 9098 | 7734 | 85.0% | 775 | 8.5% | 312 | 3.4% | 3906 | 2708 | 69.3% | 452 | 11.6% | 533 | 13.6% |
| Colon and rectum | 28040 | 25536 | 91.1% | 535 | 1.9% | 1275 | 4.5% | 37070 | 27954 | 75.4% | 1759 | 4.7% | 5684 | 15.3% |
| Corpus and uterus | 13566 | 12440 | 91.7% | 19 | 0.1% | 782 | 5.8% | 9642 | 7952 | 82.5% | 24 | 0.2% | 1315 | 13.6% |
| Esophagus | 2839 | 2523 | 88.9% | 12 | 0.4% | 226 | 8.0% | 4101 | 2945 | 71.8% | 50 | 1.2% | 850 | 20.7% |
| Eye and orbit | 679 | 605 | 89.1% | 15 | 2.2% | 38 | 5.6% | 680 | 495 | 72.8% | 13 | 1.9% | 128 | 18.8% |
| Kaposi sarcoma2 | 711 | 682 | 95.9% | __* | __* | 13 | 1.8% | 173 | 135 | 78.0% | __* | __* | 27 | 15.6% |
| Kidney and renal pelvis | 11633 | 10348 | 89.0% | 197 | 1.7% | 716 | 6.2% | 11343 | 8242 | 72.7% | 227 | 2.0% | 2168 | 19.1% |
| Liver and intrahepatic bile duct | 9107 | 8382 | 92.0% | 39 | 0.4% | 458 | 5.0% | 9918 | 7720 | 77.8% | 41 | 0.4% | 1684 | 17.0% |
| Lung and other respiratory | 25816 | 22056 | 85.4% | 559 | 2.2% | 2233 | 8.6% | 58477 | 41862 | 71.6% | 2346 | 4.0% | 10928 | 18.7% |
| Lymphocytic leukemia | 3675 | 3344 | 91.0% | 10 | 0.3% | 206 | 5.6% | 5660 | 4257 | 75.2% | 16 | 0.3% | 1134 | 20.0% |
| Lymphoma | 16124 | 14598 | 90.5% | 408 | 2.5% | 720 | 4.5% | 17348 | 12546 | 72.3% | 635 | 3.7% | 3251 | 18.7% |
| Melanoma3 | 34033 | 29222 | 85.9% | 2549 | 7.5% | 1463 | 4.3% | 32190 | 20317 | 63.1% | 5330 | 16.6% | 5065 | 15.7% |
| Mesothelioma | 313 | 266 | 85.0% | __* | __* | 34 | 10.9% | 1064 | 758 | 71.2% | __* | __* | 250 | 23.5% |
| Myeloid and monocytic leukemia | 4583 | 3448 | 75.2% | 39 | 0.9% | 441 | 9.6% | 5947 | 3754 | 63.1% | 75 | 1.3% | 1481 | 24.9% |
| Myeloma | 3808 | 3425 | 89.9% | 61 | 1.6% | 210 | 5.5% | 6437 | 4930 | 76.6% | 58 | 0.9% | 1117 | 17.4% |
| Oral cavity and pharynx | 13197 | 11466 | 86.9% | 617 | 4.7% | 712 | 5.4% | 10831 | 7503 | 69.3% | 965 | 8.9% | 1797 | 16.6% |
| Ovary4 | 5303 | 4820 | 90.9% | __* | __* | 341 | 6.4% | 4631 | 3795 | 81.9% | __* | __* | 624 | 13.5% |
| Pancreas | 6491 | 5818 | 89.6% | 3 | 0.0% | 453 | 7.0% | 13223 | 10090 | 76.3% | 11 | 0.1% | 2469 | 18.7% |
| Penis and other male genital organs | 587 | 503 | 85.7% | 36 | 6.1% | 21 | 3.6% | 649 | 421 | 64.9% | 42 | 6.5% | 151 | 23.3% |
| Prostate5 | 43116 | 40940 | 95.0% | __* | __* | 1532 | 3.6% | 54480 | 48701 | 89.4% | __* | __* | 4284 | 7.9% |
| Stomach | 4797 | 4253 | 88.7% | 55 | 1.1% | 350 | 7.3% | 7489 | 5644 | 75.4% | 115 | 1.5% | 1335 | 17.8% |
| Testis | 3942 | 3802 | 96.4% | 70 | 1.8% | 31 | 0.8% | 90 | 68 | 75.6% | 0 | 0.0% | 18 | 20.0% |
| Thyroid and other endocrine | 17773 | 16276 | 91.6% | 88 | 0.5% | 885 | 5.0% | 4431 | 3222 | 72.7% | 26 | 0.6% | 883 | 19.9% |
| Urinary bladder and other urinary organs | 8835 | 7607 | 86.1% | 196 | 2.2% | 657 | 7.4% | 23568 | 15911 | 67.5% | 1086 | 4.6% | 4920 | 20.9% |
| Miscellaneous | 6456 | 5653 | 87.6% | 42 | 0.7% | 531 | 8.2% | 16839 | 12528 | 74.4% | 115 | 0.7% | 3288 | 19.5% |
SEER does not consider recurrences of tumors of the same histology reporting within 2 months as a new primary; both sides (left and right) of a paired organ site are generally considered independent primary cancers, with some exceptions: Kaposi sarcoma, mesothelioma, ovary, and prostate (described below)
Proportion of second order or higher primary cancers with unknown prior site ranges from 1.0% (testis, age≥65 years) to 14.3% (myeloid and monocytic leukemia, age <65 years), with median of 5.3% in ages <65 years and 2.9% in ages ≥65 years
Among breast cancer cases with a prior breast cancer in ages <65 years (n=5318), 347 (6.5%, 0.4% of total) also had a prior cancer of a different site; in ages ≥65 years (n=7181), 897 (12.5%, 1.7% of total) also had a prior cancer of a different site
Kaposi sarcoma (any site or sites) is always considered a single primary
Among melanoma cases with a prior melanoma in ages <65 years (n=2549), 199 (7.8%, 0.6% of total) also had a prior cancer of a different site; in ages ≥65 years (n=5330), 1341 (25.2%, 4.2% of total) also had a prior cancer of a different site
Bilateral epithelial tumors of the ovary within 60 days of diagnosis are a single primary
Only the first invasive adenocarcinoma of the prostate is reported to SEER
SEER coding rules specify that only the first of this cancer type is reportable (i.e., no subsequent primary tumors of the same site are reported to SEER)8